Study of Lisinopril in Heart Failure Patients


Heart failure is a progressive clinical syndrome that results in structural or functional abnormalities of the heart that disrupt the heart’s performance in pumping blood. The clinical manifestations are shortness of breath and cardiomegaly. The purpose of the study was to determine the Lisinopril therapy (dose, route of administration, frequency) in heart failure patients at the hospitalized installation of Sidoarjo Hospital. The method of collecting the data was retrospectively by health medical records at Sidoarjo Hospital from January 1 until December 31, 2020. The results showed that the health medical records sample got inclusion criteria of 20 patients. Heart failure was suffered by 12 patients (60%) male patients and 8 female patients (40%). The highest age range was 56- 65 years, with 8 patients (40%). In patients with the pattern of using combination 2, there were 9 patients (33%), combination 3 had 9 patients (33%), and combination 4 had 9 patients (33%). The highest combination of 2 was Lisinopril (1x 10 mg) po + Bisoprolol (1x 2.5 mg) po. There were 2 patients (22%). The highest combination of 3 was Lisinopril (1x5 mg) po + Bisoprolol (1x 2.5 mg) po + Furosemide (1 x 20 mg) iv. There were 2 patients (22%). The highest combination of 4 was Lisinopril (1x 10 mg) po + Bisoprolol (1x 2.5 mg) po + Furosemide (3x 40 mg) iv + Spironolactone (1x 25 mg) po. There were 3 patients (33%). The results show that there are 16 patterns of using switch therapy.

Keywords: lisinopril, heart failure, hospitalization

[1] Parker, JT, Yee, GC, Posey, LM, Haines, ST, Nolin, TD, & Ellingrod V. Pharmacotherapy: A Pathophysiologic Approach.. 2020;69(11)

[2] Utomo YB, et al. ‘In-hospital Mortality Reduction among Heart Failure Patients Treated with Optimal Dose of Angiotensin-Converting Enzyme Inhibitors’. Hear Sci J. 2020;1(1):8–14.

[3] PERKI. Pedoman Tatalaksana Gagal Jantung. 2nd edition. Jakarta Utara; 2020.

[4] Catapano A, Graham I, et al. The management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution [Internet]. [cited 2022 Jun 6]; Available from:

[5] Timmis A, Vardas P, et al. NT-E heart, 2022 undefined. European Society of Cardiology: cardiovascular disease statistics 2021. [Internet]. [cited 2022 Jun 7]; Available from:

[6] Journal EH. 2015 undefined. A review of the JNC 8 blood pressure guidelines. [Internet]. [cited 2022 Jun 6]; Available from: 42/3/226/129946


[8] Purwanto BT. Siswandono. Hubungan Struktur, Sifat Kimia Fisika dengan Proses Absorpsi, Distribusi, dan Eskresi Obat. Siswandono, editor. Kim Med 1. 2016;65–92.

[9] Brower G, Levick S, Heart JJ. -, Circulation L and, 2015 undefined. Differential effects of prevention and reversal treatment with lisinopril on left ventricular remodelling in a rat model of heart failure. Elsevier [Internet]. [cited 2022 Jun 6]; Available from:

[10] Barry A. Medicines management programme: preferred medicines: angiotensin-II receptor blockers. 2013 [cited 2022 Jun 6]; Available from: bitstream/handle/10147/325085/medmanageprog2.pdf?sequence=1

[11] Gao Z, Chen Z, Sun A, and XD-M in NT, 2019 undefined. Gender differences in cardiovascular disease. Elsevier [Internet]. [cited 2022 Jun 6]; Available from:

[12] Kusumawaty J, Hidayat N, Ginanjar E. Sex Relationship with Hypertension Intensity in the Elderly in the Working Area of the Lakbok Health Center, Ciamis Regency. Mutiara Med J. [Internet]. 2016 [cited 2022 Jun 6]; Available from:

[13] Gencer B, Koskinas KC, Karagiannis A, Nanchen D, Auer R, Carballo D, et al. American College of Cardiology (ACC) and European Society of Cardiology/ European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary. Am Hear Assoc [Internet]. 2017 Nov 1 [cited 2022 Jun 6];6(11). Available from:

[14] Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation. 2003 Jul;108(3):250–2.

[15] Widiyaningsih W, Kusyati E. Hemodinamik Pasien Akut Miokard Infark (AMI) Di Ruang Perawatan Kritis. J Holist Nurs Sci. 2019;6(1):22–7.

[16] Kannan A, Janardhanan R. Hypertension as a risk factor for heart failure. Curr Hypertens Rep. 2014 Jul;16(7):447.

[17] Wowor R. Hubungan antara Kebiasaan Merokok dan Hipertrofi Ventrikel Kiri pada Laki-laki Dewasa Muda dengan Obesitas Sentral’. J BIOMEDIK JBM. 2018;10(3):174– 9.

[18] Kamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, et al. Cigarette smoking and incident heart failure: insights from the jackson heart study. Circulation. 2018 Jun;137(24):2572–82.

[19] Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: the basis for the chronotherapy of hypertension. Adv Drug Deliv Rev. 2007 Aug;59(9-10):904–22.

[20] Lopez E, Parmar M. Pendela V, [Internet] JT-S, 2022 undefined. Lisinopril. [Internet]. [cited 2022 Jun 6]; Available from:

[21] Ansari Saleh D, Brig Jend Hasan Basri J. Cahaya Fakultas Matematika dan Ilmu Pengetahuan Alam Universitas Lambung Mangkurat Jalan Yani Km NA. Study of the Use of Beta-Blocker Class Drugs in Inpatients of Ansari Saleh Banjarmasin Hospital. Udayana J Pharm [Internet]. 2020 [cited 2022 Jun 6];9(2):123– 33. Available from: access/wayback/

[22] Leny Nopitasari B, Nurbaety B, Zuhroh H. Evaluation of the Use of Antihypertensive Drugs in Outpatient Heart Failure Patients at the Regional General Hospital of West Nusa Tenggara Province. Lumbung Farm J. [Internet]. 2020 [cited 2022 Jun 6];1(2). Available from:

[23] McInnes GT. The differences between ACE inhibitor-treated and calcium channel blocker-treated hypertensive patients. J Clin Hypertens (Greenwich). 2003;5(5):337–44. [cited 2022 Jun 6] Available from:

[24] Katzung BG, Masters SB. dan Trevor AJ. Farmakologi Dasar & Klinik volume 2. 12 th edit. Al RS et, editor. Jakarta: Kedokteran EGC; 2014.